Status:
COMPLETED
Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to rem...
Eligibility Criteria
Inclusion
- HIV positive
- LPV/RTV-based HAART for at least 6 months
- HIV-1 RNA less than 50c/mL (confirmed)
- Non-HDL higher than 160 mg/dL
- CD4 of at least 50 cells/mL
Exclusion
- Use of lipid-lowering agents
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2006
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT00120393
Start Date
January 1 2004
End Date
May 1 2006
Last Update
February 5 2010
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Phoenix, Arizona, United States
2
Local Institution
Bakersfield, California, United States
3
Local Institution
Los Angeles, California, United States
4
Local Institution
San Francisco, California, United States